Longboat Amniotics AB recruits a new CEO in Kåre Engkilde, PhD
March 18, 2020
The Board of Longboat Amniotics announces a change of CEO in the company as from June 1st. Kåre Engkilde, PhD Immunology, currently working for Agilent Technologies in Denmark where he is Development Manager, Clinical & Medical Affairs, is appointed as Longboat’s new CEO as of June. Before working for Agilent, Kåre also worked for Bioneer with Mesenchymal Stem Cells, which is the focus area of Longboat. Current CEO, Anders Månsson, will remain as CEO until May 31st, and during the month of May he will overlap with Kåre who will then work as Head of Development & Partnering, duties which he will continue to perform also as CEO. Anders Månsson will remain a member of the board of the company.
– Longboat will during the course of the year scale up operations, aiming for a listing in 2020, says Chairman of the Board, Christer Fåhraeus. We intend to build our own GMP lab during the course of the year, further expand our patent portfolio, start working on an indication specific development program inside the company, and solicit potential license partners for our stem cells in areas outside of our own development focus. Anders Månsson has served the company well in defining business models, setting the direction for the company, and recruiting the right team for implementation. But the daily execution of the strategy going forward will require a CEO with further scientific depth, hence the change, he adds.
Longboat Amniotics AB is a biotech company with serial entrepreneur Christer Fåhareus as partner and Chairman of the Board. Longboat has two therapeutic focus areas. One is Mesenchymal Stem Cells and the other one is Human Pulmonary Surfactant. Both components are extracted from the amniotic fluid from planned C-sections, hence the company name – “Amniotics”.
Stem Cells are immature cells that through cell division can create cells of several different types of tissue. Mesenchymal Stem Cells can e.g. produce cells able to regenerate tissue of bone, cartilage, muscles and fat, which could be applicable in a wide array of degenerative diseases.
For further inquiry into this topic, please contact
Chairman of the Board, Longboat Amniotics AB